Genome News and Research

RSS

SARS‑CoV‑2 Omicron variant escapes monoclonal antibodies

Researchers determine the neutralizing activity of four mAbs against ten strains of SARS-CoV-2.

9 Jan 2022

Omicron variant found to be much less sensitive to neutralizing antibodies than Delta

The Omicron variant was detected for the first time in South Africa in November 2021 and has since spread to many countries.

7 Jan 2022

Levels of infectious SARS-CoV-2 in vaccinated and unvaccinated individuals

A new study assessed the levels of infectious virus (obtained from the nasopharynx) in vaccinated and unvaccinated individuals.

7 Jan 2022

Researchers isolate Omicron variant, leveling the path to vaccine development and vaccine efficacy studies

Researchers from India have now successfully grown and isolated the Omicron variant from hamsters in vivo with further culturing in the Vero CCL-81 cells in vitro, in a step forward towards testing the effectiveness of existing SARS-CoV-2 vaccines and generation of new Omicron appropriate vaccines.

7 Jan 2022

How effective are COVID-19 vaccines against the Omicron and Delta variants?

Researchers study the effectiveness of COVID-19 vaccines against the SARS-CoV-2 Omicron and Delta variants.

6 Jan 2022

Researchers identify how a critical schistosomiasis drug works on the molecular level

Independent teams from Texas Biomedical Research Institute and the Medical College of Wisconsin have published two papers in Science Translational Medicine identifying how the only approved drug to treat schistosomiasis, a widespread parasitic worm infection, works on the molecular level.

6 Jan 2022

Research may pave the way for designing new therapies to combat schistosomiasis

Neglected tropical diseases (NTDs) represent a group of about 20 conditions that affect more than a billion people worldwide.

6 Jan 2022

Study identifies current mechanism of action behind reduced severity of Omicron variant COVID-19 infection

New research shows evidence that the Omicron variant is less severe compared to the Delta variant.

6 Jan 2022

Emergence of a new SARS-CoV-2 variant from Southern France

A new study has described the emergence of another new SARS-CoV-2 variant from south-eastern France with Cameroonian origin.

6 Jan 2022

Host kinase identified as an inhibition target for SARS-CoV-2

In this experiment, the chemical probe SGC-CK2-1 inhibited virus replication at nanomolar concentration, showing a highly selective effect on the kinase.

6 Jan 2022

Streamlined, efficient approaches to cell culture spectrometry and analysis

As demand for the high throughput production of high quality, highly specialized and reliable cell culture products continues to rise, laboratories and manufacturers need to move away from traditional manual analysis methods in favor of advanced real-time analysis using power spectroscopic methods.

From Thermo Fisher Scientific – Pharmaceutical and Biopharmaceutical Solutions 6 Jan 2022

PhoreMost and POLARISqb announce a multi-target collaboration to investigate next-generation cancer therapies

PhoreMost Limited and Polaris Quantum Biotech (POLARISqb) today announced a collaboration to study oncology targets currently considered undruggable.

From PhoreMost 6 Jan 2022

SARS-CoV-2 appears to persist in organs throughout the body for months

The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), leads to asymptomatic or mild symptoms in most cases. However, in a significant minority, it causes moderate or severe disease, with lung damage and sometimes multi-organ dysfunction, the origin of which is currently a matter of intense debate.

6 Jan 2022

Genome News and Research

SARS‑CoV‑2 Omicron variant escapes monoclonal antibodies

Omicron variant found to be much less sensitive to neutralizing antibodies than Delta

Levels of infectious SARS-CoV-2 in vaccinated and unvaccinated individuals

Researchers isolate Omicron variant, leveling the path to vaccine development and vaccine efficacy studies

How effective are COVID-19 vaccines against the Omicron and Delta variants?

Researchers identify how a critical schistosomiasis drug works on the molecular level

Research may pave the way for designing new therapies to combat schistosomiasis

Study identifies current mechanism of action behind reduced severity of Omicron variant COVID-19 infection

Emergence of a new SARS-CoV-2 variant from Southern France

Host kinase identified as an inhibition target for SARS-CoV-2

Streamlined, efficient approaches to cell culture spectrometry and analysis

PhoreMost and POLARISqb announce a multi-target collaboration to investigate next-generation cancer therapies

SARS-CoV-2 appears to persist in organs throughout the body for months

Scientists estimate transmission advantage of Omicron over Delta variant as +105%

Scientists discover a division of labor between genetic switches

New compound could combat multidrug-resistant pathogens in healthcare settings

Exploring SARS-CoV-2-like viruses to mitigate the risk of zoonotic transmission to humans

Hospitalization and death associated with SARS-CoV-2 Omicron variant compared to Delta variant

Comparison of the mutational profile of Omicron with other SARS-CoV-2 lineages

Nucleocapsid protein preferentially binds to structured and longer RNA to deliver viral proteins in host circulation

The art of CRISPR: The power and promise of gene editing eBook

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

Latest News